Gapping down
In reaction to earnings/guidance:
- LULU -12.1%, ESPR -8.7%, FWRG -7.1%, STAA -5.2%, M -5.1%, NVTA -3.5%, RRGB -2.4%, LTH -2.1%, NVCR -2%, AYI -1.6%, BCRX -1%
Other news:
- IDYA -5% (proposed clinical study may proceed to evaluate IDE161 in solid tumors)
- SCLX -5% (entered into a Standby Equity Purchase Agreement)
- MOLN -4.9% (Provides Updates at 41st Annual JPM Healthcare Conference)
- HRMY -4.8% (CEO John C Jacobs is stepping down; CMO Jeffrey M. Dayno, MD, appointed interim CEO, effective immediately)
- JWN -4.6% (in sympathy with M guidance)
- KSS -4.6% (in sympathy with M guidance)
- BILI -3.5% (proposed notes repurchases and equity offering)
- BCAB -2.9% (files for $200 mln mixed securities shelf offering)
- AGIO -1.3% (Unveils 2023-2026 Value-driving Catalysts Enabling Company's Vision to Transform Patient Outcomes in Rare Diseases)
- SAGE -1.3% (to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference)
- GTHX -1.3% (upcoming 2023 readouts from its Phase 2 and Pivotal Phase 3 clinical trials of trilaciclib)
Analyst comments:
- DASH -3.7% (downgraded to Underweight from Neutral at Piper Sandler)
- CTSH -1.7% (downgraded to Underperform from Neutral at BofA Securities)
- BL -0.9% (downgraded to Neutral from Overweight at Piper Sandler)